Genetics services company 23andMe, previously backed by Alphabet, Illumina, WuXi PharmaTech and Johnson and Johnson, secured a large $250m round.
23andMe, the US-based genetics services provider received $250m in a round led by venture capital firm Sequoia Capital last week, at a $1.5bn pre-money valuation. Financial services group Fidelity Management & Research (FMR) also took part in the round, as did family office Euclidean Capital, investment firms Altimeter Capital and Casdin Capital, and research support organisation Wallenberg Foundation.
23andMe operates a consumer genetics service allowing users to send a DNA sample for analysis,…
